[Clinical Efficacy and Mechanisms of Actions of the Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and High Risk of Cardiovascular Diseases]

S R Gilarevsky

doi:10.18087/cardio.2021.4.n1549

[Clinical Efficacy and Mechanisms of Actions of the Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and High Risk of Cardiovascular Diseases]

Kardiologiia. 2021 May 4;61(4):66-72. doi: 10.18087/cardio.2021.4.n1549.

[Article in Russian]

Author

S R Gilarevsky¹

Affiliation

¹ Russian Medical Academy of Continuing Professional Education of the Ministry of Health of the Russian Federation, Moscow.

PMID: 33998411
DOI: 10.18087/cardio.2021.4.n1549

Abstract

The article discusses issues of reducing the risk for cardiovascular diseases (CVDs) in patients with type 2 diabetes mellitus during the treatment with modern hypoglycemic drugs, specifically glucagon-like peptide-1 receptor agonists.

MeSH terms

Cardiovascular Diseases* / etiology
Cardiovascular Diseases* / prevention & control
Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Glucagon-Like Peptide-1 Receptor Agonists*
Humans
Hypoglycemic Agents
Treatment Outcome

Substances

Hypoglycemic Agents
Glucagon-Like Peptide-1 Receptor Agonists